v3.26.1
Stockholders' equity (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Oct. 21, 2025
shares
Feb. 11, 2025
USD ($)
$ / shares
shares
Sep. 25, 2023
USD ($)
$ / shares
shares
Oct. 31, 2025
USD ($)
shares
Mar. 31, 2026
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
Stockholders’ equity [Abstract]              
Preferred stock, shares authorized (in shares)         10,000,000 10,000,000  
Preferred stock, par value (in Dollars per share) | $ / shares         $ 0.0001 $ 0.0001  
Preferred shares, shares issued (in shares)         0 0  
Preferred shares, shares outstanding (in shares)         0 0  
Common stock, shares authorized (in shares)         100,000,000 100,000,000  
Common stock, par value (in Dollars per share) | $ / shares         $ 0.0001 $ 0.0001  
Net proceeds from private placement (in Dollars) | $   $ 13,705          
Proceeds from exercises of common warrants (in Dollars) | $         $ 4,040 $ 0  
Settlement of derivative warrant liability (in Dollars) | $         241 0  
Derivative warrant liabilities (in Dollars) | $         $ 0 1,141 $ 4,359
Common Warrants 2025 [Member]              
Stockholders’ equity [Abstract]              
Warrant exercise price (in Dollars per share) | $ / shares [1]         $ 3.395    
Warrant expiration date         Sep. 25, 2028    
Common Warrant and Pre-Funded Warrant [Member]              
Stockholders’ equity [Abstract]              
Term of warrants         5 years    
2023 Common Warrants [Member]              
Stockholders’ equity [Abstract]              
Number of shares of common stock that can be purchased with warrants (in shares)       1,345,464      
Warrant exercise price (in Dollars per share) | $ / shares [2]         $ 3.003    
Warrants exercised into common stock (in shares)       1,345,464      
Proceeds from exercises of common warrants (in Dollars) | $       $ 4,040      
Warrants expired (in Shares) 1,190,927     1,190,927      
Warrant expiration date         Oct. 21, 2025    
Settlement of derivative warrant liability (in Dollars) | $         $ 241    
Related Party [Member]              
Stockholders’ equity [Abstract]              
Derivative warrant liabilities (in Dollars) | $         $ 0 $ 1,141  
2025 Private Placement [Member]              
Stockholders’ equity [Abstract]              
Common stock, shares authorized (in shares)   3,252,132          
Common stock, par value (in Dollars per share) | $ / shares   $ 0.0001          
Purchase price per common share (in Dollars per share) | $ / shares   $ 3.395          
Net proceeds from private placement (in Dollars) | $   $ 13,705          
2025 Private Placement [Member] | 2025 Pre-Funded Warrants [Member]              
Stockholders’ equity [Abstract]              
Number of shares of common stock that can be purchased with warrants (in shares)   1,166,160          
Number of shares issued upon exercise of each warrant (in shares)   1          
Warrant exercise price (in Dollars per share) | $ / shares   $ 0.0001          
2025 Private Placement [Member] | The 2025 Warrants [Member]              
Stockholders’ equity [Abstract]              
Number of shares of common stock that can be purchased with warrants (in shares)   4,418,292          
2025 Private Placement [Member] | Common Warrants 2025 [Member]              
Stockholders’ equity [Abstract]              
Number of shares issued upon exercise of each warrant (in shares)   1          
Class of warrant or right, issue price (in Dollars per share) | $ / shares   $ 0.125          
2025 Private Placement [Member] | Pre Funded Warrants2025 In Lieu Of Common Warrant [Member]              
Stockholders’ equity [Abstract]              
Warrant exercise price (in Dollars per share) | $ / shares   $ 3.3949          
2025 Private Placement [Member] | Pre-funded Warrants [Member]              
Stockholders’ equity [Abstract]              
Number of shares of common stock that can be purchased with warrants (in shares)         233,710    
2025 Private Placement [Member] | Related Party [Member]              
Stockholders’ equity [Abstract]              
Net proceeds from private placement (in Dollars) | $   $ 5,694          
2025 Private Placement [Member] | Minimum [Member] | ADAR1 Partners, LP Member | Equity investment [Member]              
Stockholders’ equity [Abstract]              
Equity Method Investment, Ownership Percentage   5.00%          
2025 Private Placement [Member] | Minimum [Member] | AIGH Investment Partners, LP [Member] | Equity investment [Member]              
Stockholders’ equity [Abstract]              
Equity Method Investment, Ownership Percentage   5.00%          
2025 Private Placement [Member] | Minimum [Member] | Related Party [Member] | Equity investment [Member]              
Stockholders’ equity [Abstract]              
Equity Method Investment, Ownership Percentage   5.00%          
2025 Private Placement [Member] | Common Warrant Share [Member]              
Stockholders’ equity [Abstract]              
Warrant exercise price (in Dollars per share) | $ / shares   $ 3.395          
2025 Private Placement [Member] | Common Stock [Member]              
Stockholders’ equity [Abstract]              
Warrants exercised into common stock (in shares)         233,706    
2023 Private Placement [Member]              
Stockholders’ equity [Abstract]              
Common stock, par value (in Dollars per share) | $ / shares     $ 0.0001        
Warrants exercised into common stock (in shares)     1,951,371        
Common shares sold price per share (in Dollars per share) | $ / shares     $ 1.848        
Net proceeds from offering (in Dollars) | $     $ 7,338        
2023 Private Placement [Member] | Pre-funded Warrants [Member]              
Stockholders’ equity [Abstract]              
Number of shares of common stock that can be purchased with warrants (in shares)         726,750    
Number of shares issued upon exercise of each warrant (in shares)     1        
Warrant exercise price (in Dollars per share) | $ / shares     $ 0.0001        
2023 Private Placement [Member] | Common Warrant and Pre-Funded Warrant [Member]              
Stockholders’ equity [Abstract]              
Number of shares of common stock that can be purchased with warrants (in shares)     2,536,391        
Ratio of Common Warrants to Common Shares and Pre-Funded Warrants     (0.625)        
2023 Private Placement [Member] | Common Warrants [Member]              
Stockholders’ equity [Abstract]              
Number of shares issued upon exercise of each warrant (in shares)     1        
2023 Private Placement [Member] | 2023 Common Warrants [Member]              
Stockholders’ equity [Abstract]              
Warrant exercise price (in Dollars per share) | $ / shares     $ 3.003        
2023 Private Placement [Member] | Related Party [Member]              
Stockholders’ equity [Abstract]              
Net proceeds from private placement (in Dollars) | $     $ 2,500        
2023 Private Placement [Member] | Related Party [Member] | Equity investment [Member]              
Stockholders’ equity [Abstract]              
Equity Method Investment, Ownership Percentage     5.50%        
2023 Private Placement [Member] | Maximum [Member] | Pre-funded Warrants [Member]              
Stockholders’ equity [Abstract]              
Number of shares of common stock that can be purchased with warrants (in shares)     2,106,853        
2023 Private Placement [Member] | Common Stock [Member]              
Stockholders’ equity [Abstract]              
Warrants exercised into common stock (in shares)         726,750    
[1] The 2025 Common Warrants will expire on the earlier of: (i) the 60th day after the date the FDA approves the NDA for GTx-104 and (ii) September 25, 2028.
[2] Following the exercise of 1,345,464 2023 Common Warrants in October 2025, the remaining 1,190,927 2023 Common Warrants expired on October 21, 2025, which was the 60th day after the date of the acceptance by the FDA of the NDA for the Company’s product candidate GTx-104.